IL138976A0 - Insulin-like growth factor ii antisense oligonucleotide sequences adn methods of using same to modulate cell growth - Google Patents

Insulin-like growth factor ii antisense oligonucleotide sequences adn methods of using same to modulate cell growth

Info

Publication number
IL138976A0
IL138976A0 IL13897699A IL13897699A IL138976A0 IL 138976 A0 IL138976 A0 IL 138976A0 IL 13897699 A IL13897699 A IL 13897699A IL 13897699 A IL13897699 A IL 13897699A IL 138976 A0 IL138976 A0 IL 138976A0
Authority
IL
Israel
Prior art keywords
adn
insulin
methods
same
antisense oligonucleotide
Prior art date
Application number
IL13897699A
Other languages
English (en)
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Publication of IL138976A0 publication Critical patent/IL138976A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13897699A 1998-04-23 1999-04-23 Insulin-like growth factor ii antisense oligonucleotide sequences adn methods of using same to modulate cell growth IL138976A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8279198P 1998-04-23 1998-04-23
PCT/CA1999/000323 WO1999055854A2 (en) 1998-04-23 1999-04-23 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth

Publications (1)

Publication Number Publication Date
IL138976A0 true IL138976A0 (en) 2001-11-25

Family

ID=22173486

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13897699A IL138976A0 (en) 1998-04-23 1999-04-23 Insulin-like growth factor ii antisense oligonucleotide sequences adn methods of using same to modulate cell growth
IL13897799A IL138977A0 (en) 1998-04-23 1999-04-24 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL13897799A IL138977A0 (en) 1998-04-23 1999-04-24 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth

Country Status (11)

Country Link
US (2) US6417169B1 (ko)
EP (2) EP1073728A2 (ko)
JP (2) JP2002512792A (ko)
KR (2) KR20010042849A (ko)
CN (2) CN1298444A (ko)
AU (2) AU747639C (ko)
BR (2) BR9909859A (ko)
CA (2) CA2326824A1 (ko)
IL (2) IL138976A0 (ko)
NZ (2) NZ508354A (ko)
WO (2) WO1999055855A2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
KR100441201B1 (ko) * 2001-09-10 2004-07-23 대한민국 리포터 유전자를 포함하는 티벡터용 플라스미드 및 그 제조방법
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
MXPA05012620A (es) 2003-05-21 2006-05-25 Bios Chile I G S A Marcadores para celulas precancerosas y cancerosas y metodo para interferir con la proliferacion celular.
WO2005049648A2 (en) * 2003-07-09 2005-06-02 The University Of Iowa Research Foundation Chimeric or fusion constructs of insulin-like growth factor binding proteins as chemotherapeutic agents
EP1661582A1 (en) * 2003-08-21 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Cancer metastasis inhibitor
US20060193772A1 (en) * 2003-09-24 2006-08-31 Atsushi Ochiai Drugs for treating cancer
KR100818332B1 (ko) * 2006-03-21 2008-04-02 퓨리메드 주식회사 녹용으로부터 분리된 신규 인슐린 유사 성장 인자 2의 폴리펩타이드 및 이의 유전자
MX2009012421A (es) * 2007-05-17 2009-12-01 Genentech Inc Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2.
KR20120003187A (ko) * 2010-07-02 2012-01-10 한국생명공학연구원 Ｎｅｕｒｏｐｉｌｉｎ １ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법
EP2522341A1 (en) 2011-05-13 2012-11-14 Tragex Pharma Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
AU2014265142A1 (en) * 2013-05-17 2015-12-24 Medimmune, Llc Receptors for B7-H4
EP2823816A1 (en) 2013-07-09 2015-01-14 Tragex Pharma Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5766855A (en) 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
WO1993024655A1 (en) * 1992-05-27 1993-12-09 Amersham International Plc Rna analysis
JPH08506087A (ja) 1992-10-21 1996-07-02 テンプル ユニバーシティ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU1810499A (en) * 1997-12-09 1999-06-28 Children's Medical Center Corporation Antagonists of neuropilin receptor functional and use thereof

Also Published As

Publication number Publication date
BR9909859A (pt) 2000-12-19
KR20010042848A (ko) 2001-05-25
CN1298444A (zh) 2001-06-06
AU747639C (en) 2005-01-13
BR9909809A (pt) 2000-12-19
US6417169B1 (en) 2002-07-09
WO1999055855A3 (en) 2000-01-06
CA2326825A1 (en) 1999-11-04
WO1999055855A2 (en) 1999-11-04
NZ508354A (en) 2005-01-28
JP2002512793A (ja) 2002-05-08
KR20010042849A (ko) 2001-05-25
CN1298445A (zh) 2001-06-06
CA2326824A1 (en) 1999-11-04
NZ508353A (en) 2005-01-28
AU749802B2 (en) 2002-07-04
WO1999055854A2 (en) 1999-11-04
AU3402199A (en) 1999-11-16
IL138977A0 (en) 2001-11-25
AU747639B2 (en) 2002-05-16
WO1999055854A3 (en) 2000-06-29
JP2002512792A (ja) 2002-05-08
AU3402299A (en) 1999-11-16
EP1073729A2 (en) 2001-02-07
EP1073728A2 (en) 2001-02-07
US20020187954A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
IL138976A0 (en) Insulin-like growth factor ii antisense oligonucleotide sequences adn methods of using same to modulate cell growth
AU4200400A (en) Antisense oligonucleotide modulation of stat3 expression
HUP0103571A3 (en) Characterisation of gene function using double stranded rna inhibition
IL148922A0 (en) Method for enrichment of natural antisense messenger rna
EP1003916A4 (en) ANTI-SENSE OLIGONUCLEOTID COMPOSITIONS AND METHODS FOR MODULATING JNK PROTEINS
EP0831854A4 (en) OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
EP1082456A4 (en) ANTISENSE MODULATION OF THE CD40 EXPRESSION
EP0948513A4 (en) RECOMBINATION PRODUCT FOR THE DELIVERY OF ANTISENSE NUCLEIC ACIDS AND METHODS OF USE
IL143834A0 (en) Insulin-like growth factor (igf) i mutant variants
EP1337664A4 (en) METHOD FOR INTRODUCING ANTISENSE OLIGONUCLEOTIDES IN EUKARYOTIC CELLS
AU6750800A (en) Methods of inhibiting cancer cells with adnf III antisense oligonucleotides
AU8289798A (en) Antisense oligonucleotide modulation of raf gene expression
AU1245001A (en) Antisense modulation of nucleolin expression
AU8327798A (en) Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1296643A4 (en) ANTISENSE MODULATION OF TGF-BETA EXPRESSION
EP1206478A4 (en) ANTISENSE MODULATION OF THE MEKK5 EXPRESSION
AU2264001A (en) Antisense modulation of telomeric repeat binding factor 2 expression
AU3465599A (en) Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
EP0888376A4 (en) PROCESS FOR INHIBITING TUMOR CELL GROWTH
IL137177A0 (en) Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
AU4224999A (en) Antisense oligonucleotide modulation of human thymidylate synthase expression
AU2585197A (en) Antisense approach to gene inhibition
EP1034308A4 (en) PROCESS USING ANTISENSE EXPRESSION SEQUENCES TO PRODUCE CONDITIONALLY EXPRESSED MUTANT CELLS
AU5093899A (en) Antisense oligonucleotides targeted to il-15
GB2332005A9 (en) Copper ridging for inhibiting moss growth